Chewability testing in the development of a chewable tablet for hyperphosphatemia

  title={Chewability testing in the development of a chewable tablet for hyperphosphatemia},
  author={Michael Lanz and Jan Baldischweiler and B. Kriwet and Jutta Schill and John Stafford and Georgios Imanidis},
  journal={Drug Development and Industrial Pharmacy},
  pages={1623 - 1631}
Abstract The official Pharmacopeia does not include a test procedure for the in vitro estimation of the chewability of tablets and publications in the scientific literature on this subject are rare. The purpose of this study was to evaluate a number of different test procedures for assessing chewability, starting from standard breaking force and strength testing and progressing to develop new procedures that simulate the actual chewing action on tablets. A further goal was to apply these test… 

Chewable Antacid Tablets: Are Disintegration Tests Relevant?

A need for patients to be aware of the need to thoroughly chew antacid tablets upon administration and to consider testing for disintegration testing in evaluating these dosage forms as the implicit assumption by the manufacturer that patients will chew the product sufficiently may not be met in every case.

The importance of magnesium stearate in pharmaceutical industry and in the preformulation studies of medicated chewing gums

The topic of this article is the compression physics of different gum bases which can be used to prepare chewing gum tablets by direct compression. Three different gum bases, Pharmagum® C, M and S,

Sucroferric oxyhydroxide for the treatment of hyperphosphatemia

The Phase III data indicate that sucroferric oxyhydroxide has a favorable impact on other chronic kidney disease-related mineral bone disease parameters, including a fibroblast growth factor-23-lowering effect.

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric 

Sucroferric oxyhydroxide offers a new option for the treatment of hyperphosphataemia, with a high phosphate-binding capacity, minimal iron release, and low potential for iron accumulation and toxicity.

Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis

Sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence.

Novel iron-containing phosphate binders for treatment of hyperphosphatemia

Clinical 1-year data in a limited patient cohort suggested improved adherence for SO and a large randomized controlled trial showed significant reduction in hospitalizations and costs for FCH, and cost-effectiveness and the exclusion of significant harms under long-term treatment will determine the future use of both drugs.

Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

The use of iron-based phosphate binders with significant iron absorption properties could represent a novel paradigm for correcting anemia and hyperphosphatemia in CKD patients.

Current and potential treatment options for hyperphosphatemia

The inhibitors of active intestinal phosphate transport, with their very selective mechanism of action and low pill burden seem the most interesting approach; however, do not seem at present to be effective alone, in reducing serum phosphorus levels.

Iron-based phosphate binders – a new element in management of hyperphosphatemia

Two new iron-based phosphate binder therapies have recently become available in the United States, sucroferric oxyhydroxide and ferric citrate, and both have both been shown to effectively reduce serum phosphorus comparably to widely used calcium-based binders and sevelamer salts.

Phosphate binders in patients with chronic kidney disease.

Hyperphosphataemia in patients with chronic kidney disease, particularly those on dialysis, can be ameliorated by oral phosphate binders in conjunction with dietary phosphate restriction, but it remains uncertain whether they improve clinical outcomes.



The characterization of the mechanical strength of chewable tablets.

Diametral compression and flexure tests were employed to evaluate the strength of commercial samples from five manufacturers of chewable vitamin C tablets and Weibull analysis was used to assess the brittleness of these tablets.

Protocol for production of a chewable material for masticatory function tests (Optocal - Brazilian version).

The present protocol can make the production of this chewable material easier, helping in its standardization for studies on masticatory function.

Characterization and Performance of a New Direct Compression Excipient for Chewable Tablets: Xylitab®

AbstractXylitab® is a commercially available direct compression form of xylitol. Two grades of this material, Xylitab 200 and Xylitab 100, were evaluated for compaction, flow, lubrication

The influence of malocclusion on masticatory performance. A systematic review.

Malocclusions cause decreased masticatory performance, especially as it relates to reduced occlusal contacts area, and the influence of malocclusion treatment (orthognathic surgery).

Fluoride taken up by plaque, by the underlying enamel and by clean enamel from three fluoride compounds in vitro.

The interaction of fluoride with plaque and the underlying enamel was studied in an artificial mouth after topical application of three different fluoride solutions. Streptococcus mutans</

Characterization and performance of a new direct compression excipient for chewable tablets

  • Xylitab . Drug Dev Ind Pharm 1996;22:925–32
  • 1996

European Pharmacopoeia 6th Edition

  • 2007

Measurement/MIDAS%20Slim%20Jim%20BrEv%200113_spread_ final.pdf [last accessed 21

    European Pharmacopoeia 6th Edition. Strasbourg: Council of Europe

    • 2007

    Influence of composition and geometry on chewability of Egalet ADPREM tablets

    • Available from: poster_20090717.ppt [last accessed
    • 2012